Bauer, KA; Humphries, S; Smillie, B; Li, L; Cooper, JA; Barzegar, S; ... Miller, GJ; + view all Bauer, KA; Humphries, S; Smillie, B; Li, L; Cooper, JA; Barzegar, S; Rosenberg, RD; Miller, GJ; - view fewer (2000) Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thrombosis and Haemostasis , 84 (3) 396 - 400.
Full text not available from this repository.
The risk of venous thrombosis is increased in individuals who carry specific genetic abnormalities in blood coagulation proteins. Among Caucasians, the prothrombin G20210A and factor V Arg506Gln (FV R506Q) mutations are the most prevalent defects identified to date. We evaluated their influence on markers of coagulation activation among participants in the Second Northwick Park Heart Study, which recruited healthy men (aged 50-61 years) from nine general medical practices in England and Wales. They were free of clinical vascular disease and malignancy at the time of recruitment. Genotypes for the two mutations were analyzed using microplate array diagonal gel electrophoresis, and coagulation markers (factor XIIa; activation peptides of factor IX, factor X, and prothrombin; fibrinopeptide A) were measured by immunoassay. Factor VII coagulant activity and factor VIIa levels were determined by a functional clotting assay. Among 1548 men genotyped for both mutations, 28 (1.8%) and 52 (3.4%) were heterozygous for prothrombin G202 IOA and FV R506Q, respectively. The only coagulation marker that was significantly associated with the two mutations was prothrombin activation fragment FI+2 [mean +/- SD, 0.88 +/- 0.32 nmol/L in men with prothrombin G20210A (p = 0.002) and 0.89 +/- 0.30 in men with FV R506Q (p = 0.0001) versus 0.72 +/- 0.24 among non-carriers for either mutationl. This data provides conclusive evidence that heterozygosity for the prothrombin G20210A as well as the FV R506Q mutations in the general population leads to an increased rate of prothrombin activation in vivo
|Title:||Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations|
|Additional information:||UI - 20470640 LA - eng RN - 0 (Blood Coagulation Factors) RN - 0 (Peptide Fragments) RN - 0 (prothrombin fragment 1.2) RN - 9001-24-5 (Factor V) RN - 9001-26-7 (Prothrombin) PT - Journal Article PT - Multicenter Study DA - 20010108 IS - 0340-6245 SB - IM CY - GERMANY JC - VQ7|
|Keywords:||abnormalities, ACTIVATION, Aged, As, ASSAY, Blood, Blood Coagulation, Blood Coagulation Factors, clinical, Comparative Study, DEFECTS, disease, epidemiology, etiology, Factor V, Factor VII, Factor XIIa, factors, Fibrinopeptide A, functional, genetic, genetics, Genotype, Great Britain, HEALTHY, heart, Heterozygosity, Heterozygote, Immunoassay, in vivo, in-vivo, individuals, LEVEL, Male, MALIGNANCIES, medicine, MEN, metabolism, Middle Age, Multicenter Studies, Mutation, MUTATIONS, myocardial infarction, peptide, Peptide Fragments, Peptides, physiology, Point Mutation, population, PROTEIN, Proteins, Prothrombin, Risk, Risk Factors, Support, Non-U.S.Gov't, Support, U.S.Gov't, Non-P.H.S., SYSTEM, Thrombophilia, Thrombosis, TIME, USA, vascular, Vascular Disease, Venous, Venous Thrombosis, Wales|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science|
Archive Staff Only: edit this record